Cover Image
市場調查報告書

緩慢型淋巴瘤 : 開發中產品分析

Indolent Lymphoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213069
出版日期 內容資訊 英文 213 Pages
訂單完成後即時交付
價格
Back to Top
緩慢型淋巴瘤 : 開發中產品分析 Indolent Lymphoma - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 213 Pages
簡介

緩慢型淋巴瘤是T細胞淋巴瘤的一種,其特徵為增殖、擴散的速度緩慢。主要症狀有淋巴結腫及咳嗽、胸痛或是呼吸困難、盜汗、倦怠感、食欲不振等。主要治療法有化療及放射線治療等。

本報告提供全球各國治療緩慢型淋巴瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

緩慢型淋巴瘤概要

治療藥的開發

  • 緩慢型淋巴瘤開發中產品:概要
  • 緩慢型淋巴瘤開發中產品:比較分析

各企業開發中的緩慢型淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品

緩慢型淋巴瘤治療藥:開發中的產品一覽(各企業)

緩慢型淋巴瘤開發治療藥的企業

  • AbbVie Inc
  • Affimed GmbH
  • Altor BioScience Corporation
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Juno Therapeutics Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • MorphoSys AG
  • Novartis AG
  • Seattle Genetics, Inc.
  • Trillium Therapeutics Inc.

緩慢型淋巴瘤:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

緩慢型淋巴瘤治療藥:開發暫停的產品

緩慢型淋巴瘤治療藥:開發中止的產品

緩慢型淋巴瘤相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8340IDB

Summary

Global Markets Direct's, 'Indolent Lymphoma - Pipeline Review, H2 2016', provides an overview of the Indolent Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Indolent Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Indolent Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma
  • The report reviews pipeline therapeutics for Indolent Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Indolent Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Indolent Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Indolent Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Indolent Lymphoma Overview
  • Therapeutics Development
    • Pipeline Products for Indolent Lymphoma - Overview
  • Indolent Lymphoma - Therapeutics under Development by Companies
  • Indolent Lymphoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Indolent Lymphoma - Products under Development by Companies
  • Indolent Lymphoma - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Affimed GmbH
    • Altor BioScience Corporation
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc.
    • Incyte Corporation
    • Infinity Pharmaceuticals, Inc.
    • Juno Therapeutics Inc.
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • MorphoSys AG
    • Novartis AG
    • Seattle Genetics, Inc.
    • Trillium Therapeutics Inc.
  • Indolent Lymphoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AFM-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALT-803 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bendamustine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-836826 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blinatumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BTH-1677 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DI-B4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • duvelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entospletinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-40093 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab + MEDI-0680 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3023414 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOR-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obinutuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ofatumumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEA-CD40 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTI-621 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venetoclax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Indolent Lymphoma - Dormant Projects
  • Indolent Lymphoma - Discontinued Products
  • Indolent Lymphoma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society
      • Nov 30, 2015: New Data from Bayer's Portfolio in Oncology to be Presented at ASH 2015
      • Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting
      • Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG
      • Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH
      • Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R
      • Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting
      • Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH)
      • Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Indolent Lymphoma, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Indolent Lymphoma - Pipeline by AbbVie Inc, H2 2016
  • Indolent Lymphoma - Pipeline by Affimed GmbH , H2 2016
  • Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016
  • Indolent Lymphoma - Pipeline by Amgen Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Bayer AG, H2 2016
  • Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Indolent Lymphoma - Pipeline by Celgene Corporation, H2 2016
  • Indolent Lymphoma - Pipeline by Eli Lilly and Company, H2 2016
  • Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Incyte Corporation, H2 2016
  • Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
  • Indolent Lymphoma - Pipeline by MedImmune, LLC, H2 2016
  • Indolent Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Merck KGaA, H2 2016
  • Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Indolent Lymphoma - Pipeline by MorphoSys AG, H2 2016
  • Indolent Lymphoma - Pipeline by Novartis AG, H2 2016
  • Indolent Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Indolent Lymphoma - Dormant Projects, H2 2016
  • Indolent Lymphoma - Dormant Projects (Contd..1), H2 2016
  • Indolent Lymphoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Indolent Lymphoma, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top